SAN FRANCISCO -- Research presented at the annual Crohn's and Colitis Congress included studies comparing the effectiveness ...

A study by Michigan Medicine researchers has investigated possible genetic factors for drug efficacy for children with ...

The coolest piece of outerwear we tested all season is actually pretty terrible for skiing, so we came up with some better ...

Treatment with TNF inhibitors yielded no differences in outcomes vs. other antirheumatic therapies among U.S. veterans with ...

No significant difference in the risk for MACE was observed between patients with IBD receiving JAK vs TNF inhibitors.

Bio-Thera will obtain an upfront payment of $21m and could earn up to $143.5m in development and commercial milestones.

Children with rheumatic diseases may face increased risks for COVID-19-related hospitalization, particularly those using glucocorticoids, rituximab, or mycophenolate.

Set to enter hospice care, a patient with idiopathic multicentric Castleman’s disease is now in remission after treatment with a medication identified by an AI-guided analysis ...

Bio-Thera had entered into an exclusive licensing agreement with STADA Arzneimittel AG to commercialize BAT2506 in the European Union (UK), the United Kingdom (UK), Switzerland, and selected other ...